Amphotericin Versus Posaconazole for Pulmonary Mucormycosis
Key facts
- Who runs it
- Post Graduate Institute of Medical Education and Research, Chandigarh
- Where
- India1 site in 1 countryChoose a country to see its sites
- Trial code
- Status
- Completed
- Phase
- Phase 2
- People taking part
- 82 people enrolled
- Started
- 1 Jul 2022
- Ended
- 1 Feb 2026
- Type of study
- Interventional, 2 groupsOne group gets an existing treatment, for comparison.
- Treatments tested
- Posaconazole 600 mg followed by posaconazole 300 mg once daily
- Liposomal Amphotericin B
- Record updated
- 22 May 2026
Who can take part
- Age
- 13 years and older
- Sex
- Women and men
- Healthy volunteers
- Cannot take part
Show the full registry criteria (6)Hide the full registry criteria
Who can take part
- Subjects with proven or probable pulmonary mucormycosis. Participants with a suspicion of pulmonary mucormycosis (as defined previously) based on compatible clinical presentation and compatible imaging will be screened for inclusion in the study
Who cannot take part
- Already received >4 days of antifungals prior to randomization into the study
- Failure to provide informed consent
- Contraindications or hypersensitivity to amphotericin B, posaconazole or their components
- Pregnant women
- High chances of mortality within 48 hours of enrolment into the study; Subjects with possible pulmonary mucormycosis will also be excluded, if their diagnosis is not confirmed within four working days of enrollment
Where is this trial?
It has sites in one country. Choose a country to see its sites.
About the trial
What the trial wants to find out
Pulmonary mucormycosis is a serious illness with high morbidity and mortality (approximately 57%). Surgery and antifungal therapy are central in the management of mucormycosis. Unlike rhino-orbital mucormycosis, surgery is not feasible in several patients with pulmonary mucormycosis. Hence, treatment is primarily with antifungal therapy. Amphotericin B is the standard of care in the medical management of mucormycosis. However, amphotericin B is expensive, has significant adverse events, and is available only in parenteral formulation. Posaconazole is effective against Mucorales, and is currently approved for salvage therapy of mucormycosis. Recent evidence suggest that in several patients, posaconazole may be effective as a monotherapy upfront. In the current study posaconazole versus amphotericin B will be evaluated for the management of pulmonary mucormycosis in a randomized clinical trial.
The 2 groups in the trial
- Amphotericin B arm (standard of care)Existing treatment, for comparison
Intravenous liposomal amphotericin B \[5 mg/kg per day\] for at least 4 weeks followed by maintenance therapy. Maintenance therapy (after four weeks of treatment initiation) will be continued for at least 12 weeks or longer as decided by the treating physician. The maintenance therapy will be posaconazole. However, if therapeutic drug monitoring is not possible or the participants opt to use isavuconazole or amphotericin, the same will be permitted and noted
Treatment: Liposomal Amphotericin B
- Posaconazole armTreatment being tested
Combination of liposomal amphotericin B (5 mg/kg per day) and posaconazole for first 7 days followed by oral posaconazole only (for induction as well as maintenance therapy). The first four weeks of therapy will be called induction therapy
Treatment: Posaconazole 600 mg followed by posaconazole 300 mg once daily and Liposomal Amphotericin B
Data and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- A Randomized Controlled Trial of Amphotericin B Versus Posaconazole for Treating Pulmonary Mucormycosis
- Record updated
- 22 May 2026